Recent Updates
Recently added Catalysts
OGN Positive Sentiment

Riassunto: Sun Pharma firma un accordo definitivo per acquisire Organon

Monday, April 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sun Pharmaceutical Industries Limited has announced a definitive agreement to acquire Organon & Co. for $14.00 per share, amounting to a total valuation of $11.75 billion. This acquisition reflects Sun Pharma's strategic growth ambitions and confidence in Organon's business potential. The transaction will be conducted in cash.
Price reaction · baseline $11.26 (2026-04-24 close) · 10 other OGN headline(s) in the window, move may be shared
day 0 close
+16.9%
day 1 · peak
+18.3%
day 3
+17.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sun Pharma is acquiring Organon, indicating growth strategy.
  • The acquisition is valued at $11.75 billion, showcasing confidence in Organon's value.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+54%
120-day peak, hindsight
Typical move
3.1%
average across 5 past catalysts
Lead asset
MK0653A, ezetimibe simvastatin
Phase 3 · Type 2 Diabetes Mellitus

Full Press Release Details

MUMBAI, India e JERSEY CITY, N.J.--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (insieme alle sue aziende controllate e/o associate, “Sun Pharma”) e Organon & Co. (NYSE: OGN) (“Organon”) oggi ha annunciato di aver stretto un accordo definitivo che prevede l'acquisto da parte di Sun Pharma di tutte le azioni rimaste di Organon al costo di 14,00 dollari l'una in una transazione in contanti basata su una valutazione aziendale di 11,75 miliardi di dollari.
Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

Frequently Asked Questions

What is the acquisition price for Organon?

Sun Pharma is acquiring Organon for $14.00 per share.

What is the total valuation of the acquisition?

The total valuation of the acquisition is $11.75 billion.

Who is acquiring Organon?

Sun Pharmaceutical Industries Limited is acquiring Organon.

Is the acquisition a cash transaction?

Yes, the acquisition will be conducted in cash.

ShareAdd on Google
Tags: OGN Viatris Investor Conferences Healthcare Sun Pharma Organon acquisition biopharma merger
Last updated: Apr 27, 2026

Biotech snapshot

Cash runway
$1132M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MK0653A, ezetimibe simvastatinPhase 3
Type 2 Diabetes Mellitus →

Catalyst track record

+54%
best trade around OGN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for OGN.

See every catalyst's timing & PoA →